The vulnerable plaque: The real villain in acute coronary syndromes

Open Cardiovascular Medicine Journal

Volumn 5, Issue 1, 2011, Pages 123-129

  Liang, Michael ^a   Puri, Aniket ^a,b   Devlin, Gerard ^a  

^a WAIKATO HOSPITAL   (New Zealand)

^b KING GEORGE'S MEDICAL UNIVERSITY   (India)

Author keywords

Coronary artery disease; Vulnerable plaque

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIBIOTIC AGENT; ANTIOXIDANT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; CLOPIDOGREL; CYCLOOXYGENASE 2 INHIBITOR; DARAPLADIB; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FOLIC ACID; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INFLUENZA VACCINE; METALLOPROTEINASE INHIBITOR; OMEGA 3 FATTY ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ANTAGONIST; ROSUVASTATIN; SUCCINOBUCOL;

ACUTE CORONARY SYNDROME; ANGIOCARDIOGRAPHY; ARTERIAL WALL THICKNESS; ARTERY RUPTURE; ARTICLE; ATHEROMA; ATHEROSCLEROTIC PLAQUE; CORONARY ARTERY SURGERY; CORONARY ARTERY THROMBOSIS; CORONARY STENT; DIAGNOSTIC VALUE; DISEASE MARKER; DISEASE PREDISPOSITION; DRUG ELUTING STENT; DYSLIPIDEMIA; HEART CATHETERIZATION; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; IMAGE QUALITY; INTRAVASCULAR ULTRASOUND; INVASIVE PROCEDURE; MULTIDETECTOR COMPUTED TOMOGRAPHY; NON INVASIVE PROCEDURE; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTICAL COHERENCE TOMOGRAPHY; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY;

EID: 80053497765     PISSN: None     EISSN: 18741924     Source Type: Journal    
DOI: 10.2174/1874192401105010123     Document Type: Article

References (49)

1. Fuster V, Fayad ZA, Badimon JJ. Acute coronary syndromes: biology. Lancet 1999; 353(Suppl 2): SII5-9.
2. Libby P. Molecular bases of the acute coronary syndromes. Circulation 1995; 91: 2844-50.
3. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation 1995; 92: 657-71.
4. Fuster V, Lewis A. Conner Memorial Lecture. Mechanisms leading to myocardial infarction: insights from studies of vascular biology. Circulation 1994; 90: 2126-46.
5. Loree HM, Tobias BJ, Gibson LJ, Kamm RD, Small DM, Lee RT. Mechanical properties of model atherosclerotic lesion lipid pools. Arterioscler Thromb 1994; 14: 230-4.
6. DM. George Lyman Duff memorial lecture. Progression and regression of atherosclerotic lesions. Insights from lipid physical biochemistry. Arteriosclerosis 1988; 8: 103-29.
7. Lundberg B. Chemical composition and physical state of lipid deposits in atherosclerosis. Atherosclerosis 1985; 56: 93-110.
8. Kannel WB, Dawber TR, Kagan A, Revotskie N, Stokes J, 3rd. Factors of risk in the development of coronary heart disease--six year follow-up experience. The Framingham Study. Ann Intern Med 1961; 55: 33-50.
9. Assmann G, Cullen P, Schulte H. The Munster Heart Study (PROCAM). Results of follow-up at 8 years. Eur Heart J 1998; 19: A2-11.
10. Akosah KO, Schaper A, Cogbill C, Schoenfeld P. Preventing myocardial infarction in the young adult in the first place: how do the National Cholesterol Education Panel III guidelines perform? J Am Coll Cardiol 2003 7; 41: 1475-9.
11. Naghavi M, Libby P, Falk E, et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation 2003; 108: 1664-72.
12. Naghavi M, Libby P, Falk E, et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies. Part II. Circulation 2003; 108: 1772-8.
13. Naghavi M, Falk E, Hecht HS, et al. From vulnerable plaque to vulnerable patient--Part III: Executive summary of the screening for heart attack prevention and education (SHAPE) task force report. Am J Cardiol 2006; 98: 2H-15H.
14. Packard RR, Libby P. Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction. Clin Chem 2008; 54: 24-38.
15. Danesh J, Erqou S, Walker M, et al. The Emerging Risk Factors Collaboration: analysis of individual data on lipid, inflammatory and other markers in over 1.1 million participants in 104 prospective studies of cardiovascular diseases. Eur J Epidemiol 2007; 22: 839-69.
16. Casas JP, Shah T, Hingorani AD, Danesh J, Pepys MB. C-reactive protein and coronary heart disease: a critical review. J Intern Med 2008; 264: 295-314.
17. Danesh J, Wheeler JG, Hirschfield GM, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004; 350: 1387-97.
18. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated Creactive protein. N Engl J Med 2008; 359: 2195-207.
19. Kaptoge S, Di Angelantonio E, Lowe G, et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 2010; 375: 132-40.
20. Eijgelaar WJ, Heeneman S, Daemen MJ. The vulnerable patient: refocusing on the plaque? Thromb Haemost 2009; 102: 231-9.
21. Naghavi M, Falk E, Hecht HS, Shah PK. The first SHAPE (Screening for Heart Attack Prevention and Education) guideline. Crit Pathw Cardiol 2006; 5: 187-90.
22. Ropers D, Rixe J, Anders K, et al. Usefulness of multidetector row spiral computed tomography with 64- x 0.6-mm collimation and 330-ms rotation for the noninvasive detection of significant coronary artery stenoses. Am J Cardiol 2006; 97: 343-8.
23. Schroeder S, Kuettner A, Leitritz M, et al. Reliability of differentiating human coronary plaque morphology using contrastenhanced multislice spiral computed tomography: a comparison with histology. J Comput Assist Tomogr 2004; 28: 449-54.
24. Smith-Bindman R, Lipson J, Marcus R, et al. Radiation dose associated with common computed tomography examinations and the associated lifetime attributable risk of cancer. Arch Intern Med 2009; 169: 2078-86.
25. Helft G, Worthley SG, Fuster V, et al. Progression and regression of atherosclerotic lesions: monitoring with serial noninvasive magnetic resonance imaging. Circulation 2002; 105: 993-8.
26. Yuan C, Zhang SX, Polissar NL, et al. Identification of fibrous cap rupture with magnetic resonance imaging is highly associated with recent transient ischemic attack or stroke. Circulation 2002; 105: 181-5.
27. Ogawa M, Ishino S, Mukai T, et al. (18)F-FDG accumulation in atherosclerotic plaques: immunohistochemical and PET imaging study. J Nucl Med 2004; 45: 1245-50.
28. Chen W, Bural GG, Torigian DA, Rader DJ, Alavi A. Emerging role of FDG-PET/CT in assessing atherosclerosis in large arteries. Eur J Nucl Med Mol Imaging 2009; 36: 144-51.
29. Alderman EL, Corley SD, Fisher LD, et al. Five-year angiographic follow-up of factors associated with progression of coronary artery disease in the Coronary Artery Surgery Study (CASS). CASS Participating Investigators and Staff. J Am Coll Cardiol 1993; 22: 1141-54.
30. Burke AP, Kolodgie FD, Farb A, Weber D, Virmani R. Morphological predictors of arterial remodeling in coronary atherosclerosis. Circulation 2002; 105: 297-303.
31. Losordo DW, Rosenfield K, Kaufman J, Pieczek A, Isner JM. Focal compensatory enlargement of human arteries in response to progressive atherosclerosis. In vivo documentation using intravascular ultrasound. Circulation 1994; 89: 2570-7.
32. Nissen SE, Yock P. Intravascular ultrasound: novel pathophysiological insights and current clinical applications. Circulation 2001; 103: 604-16.
33. Garcia-Garcia HM, Gonzalo N, Regar E, Serruys PW. Virtual histology and optical coherence tomography: from research to a broad clinical application. Heart 2009; 95: 1362-74.
34. de Korte CL, Pasterkamp G, van der Steen AF, Woutman HA, Bom N. Characterization of plaque components with intravascular ultrasound elastography in human femoral and coronary arteries in vitro. Circulation 2000; 102: 617-23.
35. Brezinski ME, Tearney GJ, Bouma BE, et al. Optical coherence tomography for optical biopsy. Properties and demonstration of vascular pathology. Circulation 1996; 93: 1206-13.
36. Sharif F, Murphy RT. Current status of vulnerable plaque detection. Catheter Cardiovasc Interv 2010 1; 75: 135-44.
37. Pijls NH, van Schaardenburgh P, Manoharan G, et al. Percutaneous coronary intervention of functionally nonsignificant stenosis: 5- year follow-up of the DEFER Study. J Am Coll Cardiol 2007; 49: 2105-11.
38. Tonino PA, De Bruyne B, Pijls NH, et al. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. N Engl J Med 2009; 360: 213-24.
39. Versteeg D, Hoefer IE, Schoneveld AH, et al. Monocyte toll-like receptor 2 and 4 responses and expression following percutaneous coronary intervention: association with lesion stenosis and fractional flow reserve. Heart 2008; 94: 770-6.
40. Ambrose JA, D'Agate DJ. Classification of systemic therapies for potential stabilization of the vulnerable plaque to prevent acute myocardial infarction. Am J Cardiol 2005; 95: 379-82.
41. Nissen SE, Nicholls SJ, Sipahi I, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006; 295: 1556-65.
42. Spratt JC, Camenzind E. Plaque stabilisation by systemic and local drug administration. Heart 2004; 90: 1392-4.
43. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145-53.
44. Liapis CD, Bell PF, Mikhailidis DP, et al. ESVS Guidelines: section B - diagnosis and investigation of patients with carotid stenosis. Curr Vasc Pharmacol 2010; 8: 682-91.
45. Liapis CD, Bell PF, Mikhailidis DP, et al. ESVS Guidelines: section A - prevention in patients with carotid artery stenosis. Curr Vasc Pharmacol 2010; 8: 673-81.
46. Liapis CD, Bell PR, Mikhailidis D, et al. ESVS guidelines. Invasive treatment for carotid stenosis: indications, techniques. Eur J Vasc Endovasc Surg 2009; 37: 1-19.
47. Serruys PW, Garcia-Garcia HM, Buszman P, et al. Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque. Circulation 2008; 118: 1172-82.
48. Kereiakes DJ, Szyniszewski AM, Wahr D, et al. Phase I drug and light dose-escalation trial of motexafin lutetium and far red light activation (phototherapy) in subjects with coronary artery disease undergoing percutaneous coronary intervention and stent deployment: procedural and long-term results. Circulation 2003; 108: 1310-5.
49. Waksman R, Leitch IM, Roessler J, et al. Intracoronary photodynamic therapy reduces neointimal growth without suppressing re-endothelialisation in a porcine model. Heart 2006; 92: 1138-44.